Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Psoriasis - topics covered
- Robert Willan - 1808
- Robert Willan: on cutaneous diseases
- Importance of the translational approach
- Demographics
- Impact of psoriasis on mental health
- Clinical features of psoriasis
- Single plaque psoriasis
- Psoriasis examples
- Guttate psoriasis
- Guttate psoriasis: examples
- Generalised pustular psoriasis
- Palmoplantar psoriasis
- Koebner phenomenon
- Koebner phenomenon: marker of disease activity
- Psoriasis: nails
- Psoriasis: nails examples
- Psoriatic arthritis
- Psoriatic arthritis: epidemiology
- Psoriatic arthritis: examples
- Comorbidities in psoriasis patients
- Psychosocial burden of psoriasis
- Psoriasis: precipitating factors
- Psoriasis: histology
- Role of T cells in psoriasis
- Key cells and mechanisms in psoriasis
- Central role of IL-17 In psoriasis pathogenesis
- Evolving concepts in psoriasis pathophysiology
- Previous regions associated with psoriasis
- New psoriasis susceptibility loci
- Psoriasis genes cluster to biological pathways
- Forms of psoriasis vulgaris and HLA-Cw0602
- Psoriasis phenotypes
- Late onset psoriasis
- “Ideal therapy” for psoriasis
- Treatment options for psoriasis
- Management of psoriasis
- Mild psoriasis
- First-line (GP-based)
- “Severe psoriasis”
- Second-line (hospital-based)
- Biologics for psoriasis
- Cytokine targets in psoriasis
- Biologic era for psoriasis: infliximab
- Ustekinumab: effective maintenance therapy
- Short-term efficacy: biologics for psoriasis
- Anti-IL-17 approaches for psoriasis
- Secukinumab efficacy: Phase 3 trials
- Role of JAKs in signalling
- Tofacitinib
- Apremilast inhibits phosphodiesterase-E4
- Efficacy of apremilast - RCT
- Stratified medicine
- Psoriasis as a model disease for stratification
- Hypothesis
- Right biologic first time
- Predicting responders: clinical markers
- Generalised pustular psoriasis
- Role of interleukin 36
- HLA Cw6 predicts response to ustekinumab
- Summary
Topics Covered
- Psoriasis
- Demographics
- Impact of psoriasis on mental health
- Clinical features of psoriasis
- Morphology
- Immunology
- Genetics
- Comorbidities in psoriasis patients
- Key cells and mechanisms in psoriasis
- Evolving concepts in psoriasis pathophysiology
- Psoriasis phenotypes
- Treatment options for psoriasis
- Current management
- Future management
- Cytokine targets in psoriasis
- Biologic era for psoriasis: infliximab
- Anti-IL-17 approaches for psoriasis
- Stratified medicine
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Griffiths, C. (2015, October 15). Psoriasis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 4, 2024, from https://doi.org/10.69645/ZPGU5302.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Chris Griffiths has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Chris Griffiths.
I'm foundation professor
of dermatology
at the University
of Manchester.
And today I'm going to
discuss with you psoriasis.
0:12
I'm going to cover
the following topics
over the course
of the lecture.
The demographics
of the disease,
what we know about
the morphology,
the phenotypes,
introduce you to
the current concepts around
the immunology of psoriasis
and the current concepts about
the genetics of the condition.
Psoriasis is not a disease
that affects just the skin,
but there are a number
of important
co-morbid conditions.
I'll then discuss the current
management of psoriasis
and how translational research
has allowed us to make
significant advances,
not just in the
current management,
but also in the proposed
future management
of the condition.
And I'll close
with a brief discussion of
how stratified medicine
will probably change
the landscape management
of psoriasis.
1:02
The story starts
about 200 years ago.
Robert Willan was the founder
of British Dermatology.
But he's important in the
context of this lecture
because he was
the first person
to accurately describe psoriasis
in a book published in 1808.
And not only did he describe
morphology,
as you can see on this slide,
but also was the first person
to accurately separate
psoriasis from leprosy.
1:32
But Robert Willan
was also a man
who was ahead of his time.
So not only did he describe
the morphology
of these lesions in his book,
"On Cutaneous Diseases,"
but he also
described the patients
who he was seeing
in his clinic in London.
And this a quote
from the book,
and he describes
his patients as,
"having the characteristics
of the sanguineous,
combined with
other appearances
belonging to
melancholic temperament."
So he is describing his patients
as being depressed,
and I'll come back to that
important issue
later in the talk.